Date: 2012-04-19
Type of information: Clinical research agreement
Compound: AVE 8112
Company: Sanofi (France) The Michael J. Fox Foundation (USA)
Therapeutic area: Neurodegenerative diseases - CNS diseases
Type agreement: collaboration
clinical research
Action mechanism: phosphodiesterase type 4 inhibitor
Disease: Parkinson’s disease
Details: Sanofi and the Michael J. Fox Foundation (MJFF) have entered into a collaboration to conduct a clinical trial to assess the safety and tolerability of AVE 8112 in patients with Parkinson’s disease.
Under the terms of the collaboration, MJFF will sponsor a phase I b clinical trial to assess the safety and tolerability of AVE8112 in patients with Parkinson’s disease. All data and results generated by the clinical trial will be owned by MJFF and shared with Sanofi. Further development plans will be based upon the results of the study. The clinical trial will be conducted at clinical sites in the United States in Baltimore, MD, and Los Angeles, CA. Patient enrollment in the study is expected to begin later this year.
Financial terms:
Latest news:
